Switch to:
Also traded in: Canada, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.04
VRX's Cash to Debt is ranked lower than
96% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.46 vs. VRX: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
VRX' s Cash to Debt Range Over the Past 10 Years
Min: -1.06  Med: 0.19 Max: No Debt
Current: 0.04
-1.06
No Debt
Equity to Asset 0.12
VRX's Equity to Asset is ranked lower than
95% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. VRX: 0.12 )
Ranked among companies with meaningful Equity to Asset only.
VRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.51 Max: 0.85
Current: 0.12
0.12
0.85
Interest Coverage 0.62
VRX's Interest Coverage is ranked lower than
95% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. VRX: 0.62 )
Ranked among companies with meaningful Interest Coverage only.
VRX' s Interest Coverage Range Over the Past 10 Years
Min: 0.17  Med: 4.31 Max: 121.91
Current: 0.62
0.17
121.91
F-Score: 4
Z-Score: 0.34
M-Score: -2.26
WACC vs ROIC
6.16%
-9.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.82
VRX's Operating margin (%) is ranked higher than
54% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.80 vs. VRX: 9.82 )
Ranked among companies with meaningful Operating margin (%) only.
VRX' s Operating margin (%) Range Over the Past 10 Years
Min: -9.32  Med: 15.51 Max: 24.68
Current: 9.82
-9.32
24.68
Net-margin (%) -7.09
VRX's Net-margin (%) is ranked lower than
79% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.05 vs. VRX: -7.09 )
Ranked among companies with meaningful Net-margin (%) only.
VRX' s Net-margin (%) Range Over the Past 10 Years
Min: -17.62  Med: 8.77 Max: 26.4
Current: -7.09
-17.62
26.4
ROE (%) -12.35
VRX's ROE (%) is ranked lower than
78% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. VRX: -12.35 )
Ranked among companies with meaningful ROE (%) only.
VRX' s ROE (%) Range Over the Past 10 Years
Min: -20.2  Med: 8.21 Max: 18.27
Current: -12.35
-20.2
18.27
ROA (%) -1.63
VRX's ROA (%) is ranked lower than
72% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. VRX: -1.63 )
Ranked among companies with meaningful ROA (%) only.
VRX' s ROA (%) Range Over the Past 10 Years
Min: -3.88  Med: 2.43 Max: 13.02
Current: -1.63
-3.88
13.02
ROC (Joel Greenblatt) (%) 22.39
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. VRX: 22.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -69.93  Med: 73.40 Max: 144.45
Current: 22.39
-69.93
144.45
Revenue Growth (3Y)(%) 53.80
VRX's Revenue Growth (3Y)(%) is ranked higher than
95% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. VRX: 53.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.9  Med: 27.70 Max: 55.3
Current: 53.8
-10.9
55.3
EBITDA Growth (3Y)(%) 67.20
VRX's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. VRX: 67.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.7  Med: 17.70 Max: 113.3
Current: 67.2
-35.7
113.3
EPS Growth (3Y)(%) 45.80
VRX's EPS Growth (3Y)(%) is ranked higher than
88% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. VRX: 45.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.1  Med: 10.40 Max: 83.1
Current: 45.8
-37.1
83.1
» VRX's 10-Y Financials

Financials (Next Earnings Date: 2016-08-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

VRX Guru Trades in Q2 2015

Kyle Bass 10,198 sh (New)
George Soros 9,254 sh (New)
Ken Fisher 1,828 sh (New)
Steven Cohen 42,900 sh (New)
John Paulson 9,000,000 sh (+339.02%)
Jeremy Grantham 1,708,746 sh (+47.82%)
Andreas Halvorsen 4,616,738 sh (+13.76%)
Private Capital 302,715 sh (+2.50%)
Glenn Greenberg 2,500 sh (unchged)
Bill Ackman 19,473,933 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Ruane Cunniff 33,884,050 sh (-0.60%)
Glenn Greenberg 5,701,010 sh (-2.99%)
Steve Mandel 5,310,143 sh (-4.66%)
Chris Davis 1,762,238 sh (-6.12%)
Joel Greenblatt 61,178 sh (-6.64%)
Lou Simpson 1,728,265 sh (-8.97%)
First Eagle Investment 1,055,332 sh (-11.45%)
Jana Partners 1,342,723 sh (-14.56%)
Wallace Weitz 716,730 sh (-21.86%)
Jeff Ubben 14,994,261 sh (-22.65%)
Diamond Hill Capital 130,617 sh (-27.23%)
Lee Ainslie 756,609 sh (-40.70%)
Jim Simons 107,789 sh (-77.35%)
» More
Q3 2015

VRX Guru Trades in Q3 2015

Leon Cooperman 484,915 sh (New)
Jeremy Grantham 8,176,586 sh (+378.51%)
Joel Greenblatt 88,677 sh (+44.95%)
Steve Mandel 7,461,780 sh (+40.52%)
Diamond Hill Capital 169,542 sh (+29.80%)
Lou Simpson 1,952,983 sh (+13.00%)
Andreas Halvorsen 4,993,353 sh (+8.16%)
Lee Ainslie 811,361 sh (+7.24%)
Ken Fisher 1,833 sh (+0.27%)
Ruane Cunniff 33,922,192 sh (+0.11%)
First Eagle Investment 1,055 sh (unchged)
Bill Ackman 19,473,933 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
First Eagle Investment 1,055,332 sh (unchged)
Steven Cohen Sold Out
George Soros Sold Out
Jana Partners Sold Out
Jim Simons Sold Out
Kyle Bass Sold Out
John Paulson 8,890,000 sh (-1.22%)
Private Capital 296,931 sh (-1.91%)
Glenn Greenberg 5,577,892 sh (-2.16%)
Wallace Weitz 630,155 sh (-12.08%)
Chris Davis 1,509,122 sh (-14.36%)
» More
Q4 2015

VRX Guru Trades in Q4 2015

Jana Partners 1,565,935 sh (New)
Steven Cohen 17,900 sh (New)
Chris Davis 3,784,012 sh (+150.74%)
Diamond Hill Capital 301,374 sh (+77.76%)
Andreas Halvorsen 7,793,397 sh (+56.08%)
First Eagle Investment 1,640,132 sh (+55.41%)
John Paulson 13,265,900 sh (+49.22%)
Lou Simpson 2,698,614 sh (+38.18%)
Private Capital 336,306 sh (+13.26%)
Glenn Greenberg 6,252,331 sh (+12.09%)
Ruane Cunniff 35,375,610 sh (+4.28%)
Jeff Ubben 14,994,261 sh (unchged)
First Eagle Investment 2,000 sh (unchged)
First Eagle Investment 2,500 sh (unchged)
Leon Cooperman Sold Out
Lee Ainslie Sold Out
Joel Greenblatt Sold Out
Wallace Weitz Sold Out
Ken Fisher Sold Out
Bill Ackman 16,591,122 sh (-14.80%)
Steve Mandel 5,829,079 sh (-21.88%)
Jeremy Grantham 4,393,848 sh (-46.26%)
» More
Q1 2016

VRX Guru Trades in Q1 2016

Joel Greenblatt 15,088 sh (New)
Signature Select Canadian Fund 153,900 sh (New)
Arnold Schneider 66,000 sh (New)
David Tepper 945,000 sh (New)
Francis Chou 976,843 sh (New)
Steven Cohen 3,574,900 sh (+19871.51%)
Chris Davis 7,240,337 sh (+91.34%)
Diamond Hill Capital 571,305 sh (+89.57%)
Bill Ackman 21,591,122 sh (+30.14%)
Private Capital 342,916 sh (+1.97%)
John Paulson 13,284,800 sh (+0.14%)
First Eagle Investment 11,970 sh (unchged)
Steven Cohen 529,600 sh (unchged)
John Paulson 169,800 sh (unchged)
John Paulson 73,100 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Steve Mandel Sold Out
Jeremy Grantham Sold Out
Andreas Halvorsen Sold Out
Jana Partners Sold Out
Lou Simpson 2,591,399 sh (-3.97%)
First Eagle Investment 1,495,332 sh (-8.83%)
Ruane Cunniff 30,308,449 sh (-14.32%)
Glenn Greenberg 2,034,281 sh (-67.46%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:HKMPY, OTCPK:HLUYY, NYSE:MNK, OTCPK:TAISF, NYSE:RDY, OTCPK:MDABY, NYSE:TARO, OTCPK:SFOSF, OTCPK:MTZPY, NAS:OPK, OTCPK:HYPMY, OTCPK:DNPUF, OTCPK:IPSEY, OTCPK:HTSUF, NAS:NBIX, NAS:ENDP, NAS:AKRX, OTCPK:APNHY, OTCPK:CHSYF, OTCPK:GEDSF » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico, VRX.Switzerland, 0QYW.UK,
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

Valeant Pharmaceuticals International Inc was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act effective June 29, 2005. In connection with the acquisition of Valeant Pharmaceuticals International (Valeant) in September 2010, Biovail was renamed Valeant Pharmaceuticals International, Inc. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products OTC, and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company or its third party manufacturers for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.

Ratios

vs
industry
vs
history
Forward P/E 3.41
VRX's Forward P/E is ranked higher than
98% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.13 vs. VRX: 3.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 5.59
VRX's Price/Owner Earnings (ttm) is ranked higher than
94% of the 271 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.32 vs. VRX: 5.59 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
VRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.64  Med: 17.36 Max: 805.48
Current: 5.59
4.64
805.48
P/B 1.32
VRX's P/B is ranked higher than
79% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.98 vs. VRX: 1.32 )
Ranked among companies with meaningful P/B only.
VRX' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 3.00 Max: 14.44
Current: 1.32
1.03
14.44
P/S 0.75
VRX's P/S is ranked higher than
87% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.77 vs. VRX: 0.75 )
Ranked among companies with meaningful P/S only.
VRX' s P/S Range Over the Past 10 Years
Min: 0.64  Med: 4.01 Max: 10.5
Current: 0.75
0.64
10.5
PFCF 3.81
VRX's PFCF is ranked higher than
95% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.87 vs. VRX: 3.81 )
Ranked among companies with meaningful PFCF only.
VRX' s PFCF Range Over the Past 10 Years
Min: 2.67  Med: 15.36 Max: 450.3
Current: 3.81
2.67
450.3
POCF 3.43
VRX's POCF is ranked higher than
94% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.82 vs. VRX: 3.43 )
Ranked among companies with meaningful POCF only.
VRX' s POCF Range Over the Past 10 Years
Min: 3.01  Med: 10.96 Max: 47.76
Current: 3.43
3.01
47.76
EV-to-EBIT 38.51
VRX's EV-to-EBIT is ranked lower than
76% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.83 vs. VRX: 38.51 )
Ranked among companies with meaningful EV-to-EBIT only.
VRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1217.7  Med: 12.60 Max: 379.7
Current: 38.51
-1217.7
379.7
EV-to-EBITDA 9.68
VRX's EV-to-EBITDA is ranked higher than
75% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.31 vs. VRX: 9.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31  Med: 15.05 Max: 106.7
Current: 9.68
-31
106.7
Shiller P/E 117.83
VRX's Shiller P/E is ranked lower than
81% of the 151 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 50.92 vs. VRX: 117.83 )
Ranked among companies with meaningful Shiller P/E only.
VRX' s Shiller P/E Range Over the Past 10 Years
Min: 9.54  Med: 46.04 Max: 449.48
Current: 117.83
9.54
449.48
Current Ratio 1.36
VRX's Current Ratio is ranked lower than
77% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. VRX: 1.36 )
Ranked among companies with meaningful Current Ratio only.
VRX' s Current Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.62 Max: 9.68
Current: 1.36
0.72
9.68
Quick Ratio 1.07
VRX's Quick Ratio is ranked lower than
73% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. VRX: 1.07 )
Ranked among companies with meaningful Quick Ratio only.
VRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.25 Max: 9.3
Current: 1.07
0.59
9.3
Days Inventory 165.04
VRX's Days Inventory is ranked lower than
73% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. VRX: 165.04 )
Ranked among companies with meaningful Days Inventory only.
VRX' s Days Inventory Range Over the Past 10 Years
Min: 115.82  Med: 138.97 Max: 157.92
Current: 165.04
115.82
157.92
Days Sales Outstanding 93.08
VRX's Days Sales Outstanding is ranked lower than
64% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. VRX: 93.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.41  Med: 74.31 Max: 106.05
Current: 93.08
43.41
106.05
Days Payable 60.98
VRX's Days Payable is ranked lower than
58% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.75 vs. VRX: 60.98 )
Ranked among companies with meaningful Days Payable only.
VRX' s Days Payable Range Over the Past 10 Years
Min: 61.25  Med: 77.59 Max: 128.67
Current: 60.98
61.25
128.67

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.44
VRX's Price/Projected FCF is ranked higher than
95% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. VRX: 0.44 )
Ranked among companies with meaningful Price/Projected FCF only.
VRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.33  Med: 2.02 Max: 11.22
Current: 0.44
0.33
11.22
Price/Median PS Value 0.18
VRX's Price/Median PS Value is ranked higher than
98% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. VRX: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
VRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.56 Max: 5.05
Current: 0.18
0.21
5.05
Earnings Yield (Greenblatt) (%) 2.56
VRX's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. VRX: 2.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 4.60 Max: 22.8
Current: 2.56
0.3
22.8
Forward Rate of Return (Yacktman) (%) 82.95
VRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
99% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. VRX: 82.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.5  Med: 16.50 Max: 89.5
Current: 82.95
2.5
89.5

More Statistics

Revenue (TTM) (Mil) $10,627
EPS (TTM) $ -2.15
Beta-1.02
Short Percentage of Float11.74%
52-Week Range $18.55 - 263.81
Shares Outstanding (Mil)343.03

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 12,950 13,772 15,201
EPS ($) 8.57 11.07 12.01
EPS w/o NRI ($) 8.57 11.07 12.01
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:VRX

Headlines

Articles On GuruFocus.com
Learn from Bill Ackman’s Mistakes Jul 18 2016 
Bill Ackman's Herbalife Settles with FTC, Stock Is Undervalued Jul 15 2016 
Bill Ackman's Herbalife Settles with FTC, Stock Is Undervalued Jul 15 2016 
Bill Ackman: Herbalife Bilking People, NBC Helping Valeant Short-Seller Make Money Jul 14 2016 
Sequoia Fund Addresses Valeant, New Buys, Board Changes in 2nd Quarter Letter Jul 13 2016 
Bernard Horn's Polaris Global Value Fund 2nd Quarter Letter Jul 12 2016 
Andreas Halvorsen Doubles Stake in Natural Gas Power Plant Company Jul 07 2016 
Steve Mandel Exits Position in Williams Companies in 1st Quarter Jun 24 2016 
Valeant CEO Joseph Papa Buys $5 Million of Company's Shares Jun 15 2016 
Ackman Cuts Stake in Air Products by Nearly 13 Million Shares Jun 13 2016 

More From Other Websites
2:32 am Valeant Pharma receives Complete Response Letter from the FDA regarding the New Drug... Jul 23 2016
[$$] Valeant: Not All Delays Are Created Equal Jul 22 2016
[$$] Overheard Jul 22 2016
CANADA STOCKS-TSX at highest close in year, 4th weekly gain; telecoms shine Jul 22 2016
‘Deficiencies’ at Bausch + Lomb manufacturing plant in Tampa put glaucoma drug on hold Jul 22 2016
Valeant Hits Another Bump Jul 22 2016
Valeant Slides as FDA Report Hampers Drug Application Jul 22 2016
Valeant just got blindsided Jul 22 2016
Valeant’s latest woe isn’t even financial Jul 22 2016
Valeant Pharmaceuticals: It Had to End Some Time Jul 22 2016
Valeant: Not All Delays Are Created Equal Jul 22 2016
Valeant (VRX) Stock Down on Concerns About Glaucoma Treatment Jul 22 2016
Morning Movers: General Electric Falls on Earnings; Valeant Drops Jul 22 2016
Valeant Drug Approval Hampered by FDA Facility Inspection Jul 22 2016
U.S. FDA raises concerns over Valeant's eye drop Jul 22 2016
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA Jul 22 2016
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA Jul 22 2016
BBP: An Outperforming Biotechnology ETF Jul 21 2016
Valeant & Endo: Imagining a World With No Drug Pricing Controversies Jul 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)